Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
      Biomarkers/*blood ; Oligopeptides/*blood ; Osteoarthritis, Knee/*blood ; Osteoarthritis, Knee/*epidemiology; Adult ; Aged ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/epidemiology ; Arthritis, Rheumatoid/etiology ; C-Reactive Protein/metabolism ; Cohort Studies ; Disease Susceptibility ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Odds Ratio ; Osteoarthritis, Knee/etiology ; Osteoarthritis, Knee/pathology ; ROC Curve
    • نبذة مختصرة :
      The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM levels have shown to be associated with disease activity and response to treatment in rheumatoid arthritis (RA). We investigated the level of blood CRPM in OA compared to RA using data from two phase III knee OA and two RA studies (N = 1591). Moreover, the association between CRPM levels and radiographic progression was investigated. The mean CRPM levels were significantly lower in OA (8.5 [95% CI 8.3-8.8] ng/mL, n = 781) compared to the RA patients (12.8 [9.5-16.0] ng/mL, n = 60); however, a significant subset of OA patients (31%) had CRPM levels (≥ 9 ng/mL) comparable to RA. Furthermore, OA patients (n = 152) with CRPM levels ≥ 9 ng/mL were more likely to develop contra-lateral knee OA assessed by X-ray over a two-year follow-up period with an odds ratio of 2.2 [1.0-4.7]. These data suggest that CRPM is a blood-based biochemical marker for early identification OA patients with an inflammatory phenotype.
    • References:
      Ann Rheum Dis. 2010 Nov;69(11):1976-82. (PMID: 20511616)
      Osteoarthritis Cartilage. 2015 Nov;23(11):1915-24. (PMID: 26521737)
      Ann Rheum Dis. 2020 Mar;79(3):400-407. (PMID: 31852669)
      Arthritis Res Ther. 2020 Mar 20;22(1):54. (PMID: 32192519)
      Clin Exp Rheumatol. 2019 May-Jun;37(3):358-366. (PMID: 30767876)
      Osteoarthritis Cartilage. 2015 Aug;23(8):1233-41. (PMID: 25865392)
      Ann Rheum Dis. 2017 Jan;76(1):179-185. (PMID: 27343253)
      Ann Rheum Dis. 2012 Jun;71(6):891-8. (PMID: 22128078)
      Ann Rheum Dis. 2017 Jan;76(1):186-195. (PMID: 27296323)
      F1000Res. 2019 Dec 12;8:. (PMID: 31885861)
      Arthritis Rheumatol. 2019 Jul;71(7):1056-1069. (PMID: 30653843)
      JAMA. 2019 Oct 8;322(14):1360-1370. (PMID: 31593273)
      Osteoarthritis Cartilage. 2015 Apr;23(4):532-43. (PMID: 25582279)
      Osteoarthritis Cartilage. 2017 Dec;25(12):1952-1961. (PMID: 28964890)
      Ann Rheum Dis. 2010 May;69(5):856-61. (PMID: 19934104)
      Osteoarthritis Cartilage. 2008 Jun;16(6):638-46. (PMID: 18362080)
      Biol Chem. 2015 Nov;396(11):1181-97. (PMID: 26040008)
      PLoS One. 2016 Mar 28;11(3):e0149329. (PMID: 27019199)
      Clin Immunol. 2005 Nov;117(2):104-11. (PMID: 16214080)
      Osteoarthritis Cartilage. 2015 Apr;23(4):550-8. (PMID: 25576879)
      Mol Immunol. 2001 Aug;38(2-3):189-97. (PMID: 11532280)
      Semin Arthritis Rheum. 1995 Oct;25(2):75-86. (PMID: 8578314)
      Clin Exp Rheumatol. 2012 May-Jun;30(3):371-9. (PMID: 22339813)
      Ann Rheum Dis. 2015 Apr;74(4):703-10. (PMID: 24363360)
      Clin Exp Rheumatol. 2016 Jul-Aug;34(4):625-33. (PMID: 27087059)
      J Korean Med Sci. 2013 Feb;28(2):287-94. (PMID: 23399828)
      Osteoarthritis Cartilage. 2011 Mar;19(3):265-71. (PMID: 21146623)
      PLoS One. 2019 Jul 24;14(7):e0219980. (PMID: 31339920)
      Lancet Respir Med. 2015 Jun;3(6):462-72. (PMID: 25770676)
      Arthritis Res Ther. 2011 Jul 29;13(4):R125. (PMID: 21801403)
      Clin J Pain. 2016 Oct;32(10):841-8. (PMID: 26633689)
      PLoS One. 2013;8(1):e54504. (PMID: 23365672)
      Arthritis Rheum. 2011 Jul;63(7):1908-17. (PMID: 21717421)
      Scand J Rheumatol. 2016;45(2):87-98. (PMID: 26484849)
      Aliment Pharmacol Ther. 2013 Nov;38(9):1086-96. (PMID: 24099470)
      Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595)
      Osteoarthritis Cartilage. 2014 Jan;22(1):7-16. (PMID: 24216058)
      Nat Rev Rheumatol. 2013 Jul;9(7):400-10. (PMID: 23545735)
      Subcell Biochem. 2020;94:499-520. (PMID: 32189313)
      Semin Arthritis Rheum. 2014 Feb;43(4):470-8. (PMID: 23932312)
    • الرقم المعرف:
      0 (Biomarkers)
      0 (Oligopeptides)
      0 (catch-relaxing peptide (Mytilus))
      9007-41-4 (C-Reactive Protein)
    • الموضوع:
      Date Created: 20210323 Date Completed: 20211025 Latest Revision: 20211025
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC7985384
    • الرقم المعرف:
      10.1038/s41598-021-86064-x
    • الرقم المعرف:
      33753821